Learning Objectives Introduction

Introduction

Watch an internationally renowned faculty discuss the optimization of cyclin-dependent kinase (CDK)4/6 inhibitor treatment for patients with breast cancer. Prof. Stephen Johnston, Prof. Nadia Harbeck and Prof. Mario Campone discuss patient selection, adverse event management and future directions for CDK4/6 inhibitors in the management of breast cancer.

The information in this activity is intended for oncologists, nurses and other healthcare professionals involved in the treatment of patients with breast cancer.

This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Breast Cancer Annual Congress in May 2019. (The live voting content is no longer active for this symposium.)

Learning objectives

After watching this touchSATELLITE SYMPOSIUM, you should be able to:

1 AMA PRA Category 1 Credits™ Date of original release: May 24, 2019 Date credits expire: May 24, 2020

Back to Education Zone

touchSATELLITE SYMPOSIUM

Addressing ongoing clinical challenges: How do we optimize patient outcomes with CDK4/6 inhibition in HR+/HER2- breast cancer?

1 AMA PRA Category 1 Credits™ Date of original release: May 24, 2019 Date credits expire: May 24, 2020

Clinical Spotlight

Hormone receptor positive (HR+) breast cancer constitutes 75% of all breast cancers.1 Single endocrine therapy (ET) was the standard treatment for patients with HR+/human epidermal growth factor receptor 2 negative (HER2-) advanced disease, but primary and secondary resistance have resulted in a poor prognosis for many patients.2 CDK4/6 inhibitors plus ET are now recommended in HR+/HER2- advanced breast cancer.3 However, many patients still receive chemotherapy or single-agent ET as first-line treatment.4,5 With no biomarkers to reliably guide CDK4/6 inhibitor use, there is no consensus on optimal treatment selection and sequencing for different patient subgroups. Emerging data are showing that disease and patient characteristics may impact on the optimal treatment strategy.6 Effective adverse event (AE) management is essential to ensure optimal treatment with CDK4/6 inhibitors, but AE management strategies remain a key unmet need in many clinical settings.7 Ongoing clinical trials with CDK4/6 inhibitors are exploring their use earlier in the disease continuum.8

 

Module 1: How do we optimize patient selection, treatment sequencing and AE management for HR+/HER2- advanced breast cancer therapy in the era of CDK4/6 inhibition?

Professor Nadia Harbeck and Professor Mario Campone provide insights into the latest data on treatment selection in HR+/HER2- advanced breast cancer. Patient and disease characteristics, factors that influence treatment sequencing and the AE profiles of CDK4/6 inhibitors and their management are discussed.

Start Module

Module 2: Clinical challenges in action: what would you do in our interactive case scenarios?

Professor Stephen Johnston presents interactive case studies of patients with advanced breast cancer and considers factors influencing treatment selection and tailoring to optimize outcomes.

Start Module

Module 3: Current challenges with CDK4/6 inhibitors in advanced breast cancer and moving forwards in early breast cancer

Professor Stephen Johnston leads a faculty discussion of questions from the audience concerning CDK4/6 inhibitors in advanced breast cancer, and a review of current studies investigating CDK4/6 inhibitors in early breast cancer.

Start Module

Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London and Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden, London, UK.

Stephen Johnston has a specialist interest in the treatment of metastatic breast cancer and his major research interests lie in understanding the mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several Phase II/III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors.

Disclosures: Consultancy for AstraZeneca, Eli Lilly, Novartis and Puma Biotechnology. Member of the speaker bureau for both Novartis and Pfizer. Institutional research funding from Pfizer.

Director General of the Institut de Cancérologie de l’Ouest (ICO) and Professor of the Department of Medicine, University of Angers, France.

Mario Campone is chair of the Early Study group and the vice-chairman of the Personalized Medicine group of Unicancer. His research interests include investigating how aberrant survival contributes to tumour escape, resistance to conventional and targeted therapies, and the identification of novel targets for innovative treatments, as well as prognostic and predictive factors for targeted therapies.

Disclosures: Advisory boards for AstraZeneca, Eli Lilly, Novartis and Pfizer. Consultancy for Pierre Fabre and Sanofi. Speaker bureau for Novartis.

 

Head of the Breast Center and holds the Chair for Conservative Oncology at the Department of Obstetrics and Gynecology, University of Munich, Germany.

Nadia Harbeck is Principal Investigator or Steering Committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).

Disclosures: Honoraria for lectures and consulting from AstraZeneca, Eli Lilly, Novartis and Pfizer.

REFERENCES